ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

UPLC-QTOF/MS-based metabolomics analysis of plasma reveals an effect of Xue-Fu-Zhu-Yu capsules on blood-stasis syndrome in CHD rats

Yuhang Zhao; Shanshan Nie; Min Yi; Ning Wu; Wenbo Wang; Zheyu Zhang; Ye Yao; Dongsheng Wang
Journal of Ethnopharmacology2019DOI: 10.1016/j.jep.2019.111908
9阅读
引用收藏
分享

摘要

Ethnopharmacological relevance<br/>Blood-stasis syndrome (BSS) is a specific ZHENG type of coronary heart disease (CHD) in traditional Chinese medicine (TCM). The Xue-Fu-Zhu-Yu (XFZY) decoction is a common herbal formula that has been used for several centuries to treat BSS, but its mechanism has not been thoroughly elucidated to date.<br/>Aim of the study<br/>In this study, serum lipid, blood haemorheology and metabolomics analyses were performed to depict a complete profile of XFZY capsules for the treatment of CHD with BSS and to reveal the potential mechanism of the XFZY capsules.<br/>Materials and methods<br/>A rat model of CHD with BSS was generated by combining a high-fat diet (HFD) with a left anterior descending coronary artery (LAD) ligation. After four weeks of treatment with XFZY capsules or simvastatin pills, an echocardiography was performed for a therapeutic evaluation. Blood samples and heart tissues were then collected for further analyses. A UPLC-QTOF/MS-based metabolomics analysis of the plasma was performed, and all metabolic features were fit by PCA and OPLS-DA pattern for the biomarker screen. The identified biomarkers were later implemented into a metabolic pathway analysis. Furthermore, we used qRT-PCR and Western blot analyses to verify the treatment effects of the XFZY capsules.<br/>Results<br/>A total of 49 metabolites (VIP>1.0, p < 0.05, RSD%<20%) were identified in the Model rats, and 27 metabolites (VIP>1.0, p < 0.05, RSD%<20%) were identified in the XFZY-H rats. The results of the pathway analysis indicated that the XFZY capsules treated CHD primarily by regulating cardiac energy, phospholipid, polyunsaturated fatty acid (PUFA) and amino acid metabolism. In addition, blood viscosity and serum lipid assays suggested that XFZY capsules could decrease serum triglycerides, total cholesterol, low-density lipoprotein cholesterol and whole blood viscosity at a low shear rate.<br/>Conclusion<br/>This study demonstrated that the XFZY capsule effectively decreases serum lipids and whole blood viscosity in CHD with BSS. The underlying metabolic mechanism mainly included improving cardiac energy supply, reducing phospholipid peroxide, maintaining the PUFA metabolic balance and regulating amino acid metabolism.<br/>Graphical abstract<br/><br/>Download high-res image (465KB)Download full-size image

学科与关键词

关键词
MetabolomicsCardiovascularMyocardial infarctionBlood-stasis syndromeTraditional Chinese medicineXue-Fu-Zhu-Yu
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Journal of Ethnopharmacology
发表日期
2019
卷期
第 241 卷
页码
111908
DOI
10.1016/j.jep.2019.111908
语言
ENGLISH
成果收录
SCIENCEDIRECT

作者

  • Y

    Yuhang Zhao (第一作者)

  • S

    Shanshan Nie

查看全部 8 位作者收起作者
  • M

    Min Yi

  • N

    Ning Wu

  • W

    Wenbo Wang

  • Z

    Zheyu Zhang

  • Y

    Ye Yao

  • D

    Dongsheng Wang

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417